BNC2: A Drug Target / Disease Biomarker (G54796)

Target Name: BNC2

NCBI ID: G54796

BNC2

BNC2: A Drug Target / Disease Biomarker

BNC2, short for B cell nuclear factor, is a protein that plays a crucial role in the development and activation of B cells, which are a type of white blood cell that plays a key role in the immune system. BNC2 has been identified as a potential drug target and has been shown to have a negative impact on the growth and survival of cancer cells.

BNC2 is a protein that is expressed in a variety of tissues, including the brain, pancreas, and spleen. It is a nuclear transcription factor, which means that it can cause changes in the amount of a specific protein in the cell. The BNC2 gene has been shown to encode a protein that is involved in the regulation of gene expression and has been implicated in the development and progression of a number of diseases, including cancer.

One of the key functions of BNC2 is its role in the development of B cells. B cells are a type of white blood cell that is responsible for producing antibodies, which are proteins that help to neutralize or destroy pathogens in the body. When a B cell encounters a pathogen, it becomes activated and begins to divide and differentiate into a specialized type of cell called a plasma cell. Plasma cells are responsible for producing antibodies, which are then released into the bloodstream to help to protect the body against the pathogen.

BNC2 plays a crucial role in the development and activation of B cells by regulating the expression of genes that are involved in the cell's development and function. For example, studies have shown that BNC2 can cause changes in the level of a protein called SMAD4, which is involved in the regulation of gene expression. This increase in the level of SMAD4 has been shown to promote the development and activation of B cells.

In addition to its role in the development of B cells, BNC2 has also been shown to have a negative impact on the growth and survival of cancer cells. Studies have shown that BNC2 can cause changes in the level of a protein called p53, which is a tumor suppressor protein. This increase in the level of p53 has been shown to inhibit the growth and survival of cancer cells.

This negative impact on cancer cells is thought to be due to BNC2's ability to cause changes in the expression of genes that are involved in cell growth and survival. For example, studies have shown that BNC2 can cause changes in the level of a protein called NF-kappa-B, which is involved in the regulation of inflammation and immune responses. These changes in NF-kappa-B have been shown to promote the growth and survival of cancer cells.

Despite its negative impact on cancer cells, BNC2 has also been shown to have a positive impact on the development and activation of B cells. Studies have shown that BNC2 can cause changes in the level of a protein called BCL-2, which is involved in the regulation of cell death. This increase in the level of BCL-2 has been shown to promote the development and activation of B cells.

In conclusion, BNC2 is a protein that plays a crucial role in the development and activation of B cells. Its ability to cause changes in the expression of genes involved in cell growth and survival makes it a potential drug target for cancer treatment. Further research is needed to fully understand the role of BNC2 in the development and progression of cancer.

Protein Name: Basonuclin 2

Functions: Probable transcription factor specific for skin keratinocytes. May play a role in the differentiation of spermatozoa and oocytes (PubMed:14988505). May also play an important role in early urinary-tract development (PubMed:31051115)

The "BNC2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BNC2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets